A Phase 1 interventional study of TAK-755 and Placebo in Sickle Cell Disease, sponsored by Shire. Completed at 14 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-04-23.
Sponsored by Shire (part of Takeda) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.
Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 384th largest by enrollment of the 559 interventional ones that give a count, is one of 36 that started in 2019, is one of 98 in phase 1, and was the 457th registered.
1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.
Browse Anemia, Sickle Cell studies →134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:
University of Maryland, Baltimore · Sites in United States
Ages 18–88
Mohsen Saidinejad · Sites in United States
Ages 5–20
St. Jude Children's Research Hospital · Sites in United States
Ages up to 22
Emory University · Sites in United States
Ages 8–18
University of Alabama at Birmingham · Sites in United States
Ages 18–50 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
733 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 158 · Phase 2 228 · Phase 3 57 · Phase 4 20
First in 1984; this study’s year is marked. 36 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 40 across 770 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 31 across the 559 interventional studies, 100 across the 168 observational. Of the 506 that completed or were terminated, 207 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
168 of 733 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
Takeda has 6 studies filed under Anemia, Sickle Cell — fewer than ten, so there is no comparison to draw.
57 of the studies in Anemia, Sickle Cell with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07247188Phase 3SanofiStudy of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease | 2027-01-07 |
| NCT04293185Phase 3bluebird bioA Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease | 2027-05 |
| NCT06989567Phase 3Asklepion Pharmaceuticals, LLCA Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis | 2027-06 |
| NCT05329649Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) | 2027-06-06 |
| NCT05477563Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease | 2027-06-09 |
Add all 57 to your calendar (.ics) → With an account.
Among the 733 studies in Anemia, Sickle Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
TAK-755 (previously known as SHP655) is a medicine used to treat sickle cell disease (SCD). The main aim of the study is to measure the safety and tolerability of TAK-755 in SCD participants.
Study participants will receive TAK-755 or placebo on Day 1. Their SCD will be treated by their doctor according to their doctor's usual clinical practice.
During the study, participants will be asked to follow-up on 13 days following SHP655 or placebo administration for safety assessment. Maximum duration of participation is expected to be about 2 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The participant has Acute Chest Syndrome (ACS), diagnosed or strongly suspected, as evidenced by a new infiltrate on chest radiograph, and one or more of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with SCD at their baseline health will receive a single intravenous (IV) infusion at one of the 3 dose levels of 40, 80 and 160 International units per kilogram (IU/kg) in a dose escalation manner.
Drug: TAK-755
Participants with SCD at their baseline health will receive placebo matched to TAK-755 of the 3 dose levels of 40 IU/kg, 80 IU/kg, and 160 IU/kg as single IV infusion.
Other: Placebo
Participants will receive TAK-755 as a single IV infusion at one of the 3 dose levels of 40 IU/kg, 80 IU/kg, or 160 IU/kg.
Also known as: recombinant ADAMTS13, BAX 930, SHP655
Participants will receive placebo matched to TAK-755 of the 3 dose levels of 40 IU/kg, 80 IU/kg, and 160 IU/kg as single IV infusion.
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this investigational product (IP) or medicinal product. TEAEs were defined as AEs that started or worsened in severity on or after the infusion of IP. A serious TEAEs was any untoward clinical manifestation of signs, symptoms or outcomes (whether considered related to investigational product or not and at any dose) which resulted in death, was life-threatening, required inpatient hospitalization, prolongation of hospitalization, was an important medical event. TEAEs included both serious and non-serious AEs.
Time frame: From date of signing informed consent up to end of study visit (Day 28)
Number of Participants Who Developed Positive Binding Anti-ADAMTS13 and Inhibitory Anti-ADAMTS13 Antibodies to TAK-755
Measurement of Anti-ADAMTS13 antibodies can be used to assess whether the body's immune system has been stimulated to react to TAK-755. Binding Anti-ADAMTS13 antibodies measure antibodies that are able to bind to ADAMTS13, whether or not the antibodies have an effect on how well ADAMTS13 works. An inhibitory Anti-ADAMTS13 antibody is antibody that both binds to ADAMTS13 and able to affect how well ADAMTS13 works. Binding and Inhibitory anti-ADAMTS13 antibodies were categorized as pre-existing, treatment-induced, and treatment-boosted. Pre-existing: anti-ADAMTS13 antibodies were detected in the baseline sample prior to infusion with TAK-755. Treatment-induced: no anti-ADAMTS13 antibodies were detected in baseline sample but were detected in any sample drawn after TAK-755 infusion. Treatment-boosted: anti-ADAMTS13 antibodies were pre-existing and were detected at any time after TAK-755 infusion at titers that were at least 4 steps higher than the titers detected before TAK-755 infusion.
Time frame: From date of signing informed consent up to end of study visit (Day 28)
Incremental Recovery (IR) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755
IR was defined as the ratio of maximum increase in plasma ADAMTS13 antigen or activity level to TAK-755 dose per body weight. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall. Here "IU/mL/IU/kg" refers to "International units per milliliter per international units per kilogram".
Time frame: Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose
Observed Maximum Concentration (Cmax) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755
Cmax was a measure of the maximum amount of drug in the plasma after the dose was given. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.
Time frame: Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose
Time to Reach Cmax (Tmax) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755
Tmax was a measure of the time to reach the maximum concentration in the plasma after the drug dose. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.
Time frame: Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose
Terminal Half-Life (t1/2) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755
t1/2 was the time required for a given drug concentration in the plasma to decrease by 50%. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.
Time frame: Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose
Mean Residence Time From Zero to Infinite (MRT0-Inf) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755
The MRT is the average time that the study product stays in the body (or plasma). The MRT0-Inf is defined as the average time from zero (pre-dose) extrapolated to infinite time (MRT0-inf). Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.
Time frame: Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose
Mean Residence Time From Zero to 72 Hours Post-dose (MRT0-72) of ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755
The MRT is the average time that the study product stays in the body (or plasma) and The MRT0-72 is defined as the average time from zero (predose) to 72 hours post-dose (MRT0-72). Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755.
Time frame: Baseline (Pre-dose), 0.25, 1, 3, 8, 24, and 72 hours post-dose
Area Under the Curve From Zero to Time of Last Quantifiable Concentration (AUC0-Last) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755
AUC0-Last was an area under the concentration-time curve from zero (pre-dose) to time of last quantifiable concentration. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.
Time frame: Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose
Area Under the Curve Time Curve From Zero to 72 Hours Post-dose (AUC0-72) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755
AUC0-72 was an area under the concentration-time curve from zero (predose) to 72 hours post-dose (AUC0-72). Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.
Time frame: Baseline (Pre-dose), 0.25, 1, 3, 8, 24, and 72 hours post-dose
Area Under the Curve From Zero to Infinite Time (AUC0-Inf) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755
AUC0-inf was area under the concentration-time curve from zero (pre-dose) extrapolated to infinite time. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.
Time frame: Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose
Systemic Clearance (CL) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755
CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC\[0-infinity\]). Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.
Time frame: Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose
Volume of Distribution at Steady State (Vss) for ADAMTS13 Activity and ADAMTS13 Antigen of TAK-755
Vss is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state which is estimated by MRT(0-inf)\*CL. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.
Time frame: Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose
Change From Baseline in Von Willebrand Factor: Antigen (VWF:Ag) at Specified Timepoints
Von Willebrand factor (vWF or VWF) is a protein that is one of several components of the coagulation system that work together to stop bleeding within the body. VWF:Ag measures the level of von Willebrand factor protein in the blood. The change from baseline in VWF:Ag concentration was measured at different time points. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the dose of IP. Change from baseline was calculated by subtracting the baseline value from the post-dose value.
Time frame: Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose
Change From Baseline in Von Willebrand Factor:Ristocetin Cofactor Activity (VWF:RCo) At Specified Timepoints
Von Willebrand factor (vWF or VWF) is a protein that is one of several components of the coagulation system that work together, to stop bleeding within the body. VWF:RCo assay is a test that measures the activity of the VWF in a plasma sample in terms of how well it is able to clump platelets together in the presence of the antibiotic ristocetin. Change from baseline in vWF:RCo concentration was measured at different timepoints. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the dose of IP. Change from baseline was calculated by subtracting the baseline value from the post-dose value.
Time frame: Baseline (Pre-dose), 0.25, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose
Change From Baseline in Platelet Count at Specified Timepoints
Blood samples were collected to analyze platelet count. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the dose of IP. Thechange from baseline was calculated by subtracting the baseline value from the post-dose value.
Time frame: Baseline (Pre-dose), 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose
Change From Baseline in Plasma Free Hemoglobin at Specified Timepoints
The plasma free hemoglobin test measures the level of hemoglobin in the plasma (that is, not contained within the red blood cells). Baseline was defined as the last non-missing measurement obtained prior to the date and time of the dose of IP. Change from baseline was calculated by subtracting the baseline value from the post-dose value.
Time frame: Baseline (Pre-dose), 3, 8, 24, 72, 120, 168, 216, 288, and 648 hours post-dose
Change From Baseline in Plasma Thrombospondin Levels at Specified Timepoints
Change from baseline in plasma thrombospondin levels over time was reported. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the dose of IP. Change from baseline was calculated by subtracting the baseline value from the post-dose value.
Time frame: Baseline (Pre-dose), 3, 8, 24, 72, 120, 168, 288, and 648 hours post-dose
This study was conducted at 9 active sites in the United States from 21 October 2019 to 26 October 2022.
| Milestone | Placebo | TAK-755: 40 IU/kg | TAK-755: 80 IU/kg | TAK-755: 160 IU/kg |
|---|---|---|---|---|
| Started | 5 | 4 | 6 | 4 |
| Completed | 5 | 3 | 6 | 4 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Protocol deviation | 0 | 1 | 0 | 0 |
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this investigational product (IP) or medicinal product. TEAEs were defined as AEs that started or worsened in severity on or after the infusion of IP. A serious TEAEs was any untoward clinical manifestation of signs, symptoms or outcomes (whether considered related to investigational product or not and at any dose) which resulted in death, was life-threatening, required inpatient hospitalization, prolongation of hospitalization, was an important medical event. TEAEs included both serious and non-serious AEs.
| Participants | Placebo | TAK-755: 40 IU/kg | TAK-755: 80 IU/kg | TAK-755: 160 IU/kg |
|---|---|---|---|---|
| Participants with TEAEs | 2 | 2 | 4 | 2 |
| Participants with Serious TEAEs | 0 | 1 | 0 | 0 |
Measurement of Anti-ADAMTS13 antibodies can be used to assess whether the body's immune system has been stimulated to react to TAK-755. Binding Anti-ADAMTS13 antibodies measure antibodies that are able to bind to ADAMTS13, whether or not the antibodies have an effect on how well ADAMTS13 works. An inhibitory Anti-ADAMTS13 antibody is antibody that both binds to ADAMTS13 and able to affect how well ADAMTS13 works. Binding and Inhibitory anti-ADAMTS13 antibodies were categorized as pre-existing, treatment-induced, and treatment-boosted. Pre-existing: anti-ADAMTS13 antibodies were detected in the baseline sample prior to infusion with TAK-755. Treatment-induced: no anti-ADAMTS13 antibodies were detected in baseline sample but were detected in any sample drawn after TAK-755 infusion. Treatment-boosted: anti-ADAMTS13 antibodies were pre-existing and were detected at any time after TAK-755 infusion at titers that were at least 4 steps higher than the titers detected before TAK-755 infusion.
| Participants | Placebo | TAK-755: 40 IU/kg | TAK-755: 80 IU/kg | TAK-755: 160 IU/kg |
|---|---|---|---|---|
| Pre-Existing Inhibitory Anti-ADAMTS13 Antibodies | 0 | 0 | 0 | 0 |
| Treatment-Induced Inhibitory Anti-ADAMTS13 Antibodies | 0 | 0 | 0 | 0 |
| Treatment-Boosted Inhibitory Anti-ADAMTS13 Antibodies | 0 | 0 | 0 | 0 |
| Pre-Existing Binding Anti-ADAMTS13 Antibodies | 1 | 1 | 2 | 2 |
| Treatment-Induced Binding Anti-ADAMTS13 Antibodies | 1 | 1 | 1 | 0 |
| Treatment-Boosted Binding Anti-ADAMTS13 Antibodies | 0 | 0 | 0 | 0 |
IR was defined as the ratio of maximum increase in plasma ADAMTS13 antigen or activity level to TAK-755 dose per body weight. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall. Here "IU/mL/IU/kg" refers to "International units per milliliter per international units per kilogram".
| IU/mL/IU/kg | TAK-755: 40 IU/kg | TAK-755: 80 IU/kg | TAK-755: 160 IU/kg |
|---|---|---|---|
| Baseline-adjusted ADAMTS13 Activity | 0.022440 ± 32.3 | 0.025227 ± 33.4 | 0.018423 ± 33.6 |
| Baseline-adjusted ADAMTS13 Antigen | 0.021809 ± 25.8 | 0.021925 ± 30.1 | 0.022012 ± 22.2 |
Cmax was a measure of the maximum amount of drug in the plasma after the dose was given. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.
| international units per milliliter | TAK-755: 40 IU/kg | TAK-755: 80 IU/kg | TAK-755: 160 IU/kg |
|---|---|---|---|
| Baseline-adjusted ADAMTS13 Activity | 0.90202 ± 33.5 | 2.0080 ± 33.2 | 2.9539 ± 33.6 |
| Baseline-adjusted ADAMTS13 Antigen | 0.49848 ± 27.9 | 1.0382 ± 30.3 | 2.0392 ± 22.2 |
Tmax was a measure of the time to reach the maximum concentration in the plasma after the drug dose. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.
| hour | TAK-755: 40 IU/kg | TAK-755: 80 IU/kg | TAK-755: 160 IU/kg |
|---|---|---|---|
| Baseline-adjusted ADAMTS13 Activity | 2.16 (0.32 to 3.03) | 1.08 (0.25 to 74.45) | 0.45 (0.32 to 1.18) |
| Baseline-adjusted ADAMTS13 Antigen | 0.45 (0.25 to 24.17) | 1.10 (0.28 to 3.48) | 0.83 (0.32 to 1.50) |
t1/2 was the time required for a given drug concentration in the plasma to decrease by 50%. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.
| hour | TAK-755: 40 IU/kg | TAK-755: 80 IU/kg | TAK-755: 160 IU/kg |
|---|---|---|---|
| Baseline-adjusted ADAMTS13 Activity | NA ± NA | 54.56 ± 28.230 | 42.22 ± 9.7253 |
| Baseline-adjusted ADAMTS13 Antigen | NA ± NA | 65.17 ± 41.728 | 46.88 ± 16.821 |
The MRT is the average time that the study product stays in the body (or plasma). The MRT0-Inf is defined as the average time from zero (pre-dose) extrapolated to infinite time (MRT0-inf). Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.
| hour | TAK-755: 40 IU/kg | TAK-755: 80 IU/kg | TAK-755: 160 IU/kg |
|---|---|---|---|
| Baseline-adjusted ADAMTS13 Activity | NA ± NA | 118.6 ± 46.170 | 87.54 ± 37.734 |
| Baseline-adjusted ADAMTS13 Antigen | NA ± NA | 116.3 ± 57.699 | 69.48 ± 23.555 |
The MRT is the average time that the study product stays in the body (or plasma) and The MRT0-72 is defined as the average time from zero (predose) to 72 hours post-dose (MRT0-72). Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755.
No measurements were reported for this outcome.
AUC0-Last was an area under the concentration-time curve from zero (pre-dose) to time of last quantifiable concentration. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.
| hour* International unit per milliliter | TAK-755: 40 IU/kg | TAK-755: 80 IU/kg | TAK-755: 160 IU/kg |
|---|---|---|---|
| Baseline-adjusted ADAMTS13 Activity | NA ± NA | 161.5 ± 28.1 | 137.2 ± 36.1 |
| Baseline-adjusted ADAMTS13 Antigen | 25.96 ± 32.9 | 79.05 ± 22.0 | 105.7 ± 27.7 |
AUC0-72 was an area under the concentration-time curve from zero (predose) to 72 hours post-dose (AUC0-72). Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.
| hour* International unit per milliliter | TAK-755: 40 IU/kg | TAK-755: 80 IU/kg | TAK-755: 160 IU/kg |
|---|---|---|---|
| Baseline-adjusted ADAMTS13 Activity | 19.77 ± 122.3 | 78.44 ± 36.8 | 92.41 ± 27.1 |
| Baseline-adjusted ADAMTS13 Antigen | 17.91 ± 22.7 | 42.86 ± 9.5 | 73.20 ± 22.0 |
AUC0-inf was area under the concentration-time curve from zero (pre-dose) extrapolated to infinite time. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.
| hour* International unit per milliliter | TAK-755: 40 IU/kg | TAK-755: 80 IU/kg | TAK-755: 160 IU/kg |
|---|---|---|---|
| Baseline-adjusted ADAMTS13 Activity | NA ± NA | 190.1 ± 45.3 | 152.5 ± 46.6 |
| Baseline-adjusted ADAMTS13 Antigen | NA ± NA | 88.34 ± 34.6 | 114.0 ± 27.5 |
CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC\[0-infinity\]). Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.
| liters per hour (L/h) | TAK-755: 40 IU/kg | TAK-755: 80 IU/kg | TAK-755: 160 IU/kg |
|---|---|---|---|
| Baseline-adjusted ADAMTS13 Activity | NA ± NA | 37.22 ± 64.3 | 74.35 ± 46.8 |
| Baseline-adjusted ADAMTS13 Antigen | NA ± NA | 51.28 ± 66.1 | 54.47 ± 54.47 |
Vss is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state which is estimated by MRT(0-inf)\*CL. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the first dose of TAK-755. Baseline-adjusted values were used for this analysis. Baseline-adjusted values at each timepoint were calculated as the measured value minus the pre-infusion (baseline) value and results were summarized overall.
| liters | TAK-755: 40 IU/kg | TAK-755: 80 IU/kg | TAK-755: 160 IU/kg |
|---|---|---|---|
| Baseline-adjusted ADAMTS13 Activity | NA ± NA | 3993 ± 48.2 | 5771 ± 17.2 |
| Baseline-adjusted ADAMTS13 Antigen | NA ± NA | 4682 ± 8.4 | 3661 ± 21.7 |
Von Willebrand factor (vWF or VWF) is a protein that is one of several components of the coagulation system that work together to stop bleeding within the body. VWF:Ag measures the level of von Willebrand factor protein in the blood. The change from baseline in VWF:Ag concentration was measured at different time points. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the dose of IP. Change from baseline was calculated by subtracting the baseline value from the post-dose value.
| Percentage of vWF Ag | Placebo | TAK-755: 40 IU/kg | TAK-755: 80 IU/kg | TAK-755: 160 IU/kg |
|---|---|---|---|---|
| Change at 0.25 hours | 5.20 ± 23.774 | -29.47 ± 17.719 | -0.96 ± 32.870 | -16.27 ± 9.341 |
| Change at 1 hour | -9.90 ± 27.518 | -19.47 ± 10.161 | 9.50 ± 20.168 | 4.00 ± 12.139 |
| Change at 3 hours | -7.80 ± 12.301 | -18.27 ± 4.670 | -0.30 ± 22.744 | NA ± NA |
| Change at 8 hours | -8.20 ± 14.245 | 13.07 ± 20.433 | -0.24 ± 15.028 | NA ± NA |
| Change at 24 hours | 0.10 ± 17.116 | 16.00 ± 34.113 | 20.42 ± 18.756 | 2.93 ± 24.981 |
| Change at 72 hours | -25.20 ± 27.695 | 8.93 ± 43.275 | 20.32 ± 25.345 | 9.47 ± 25.026 |
| Change at 120 hours | -14.40 ± 37.183 | NA ± NA | 0.67 ± 29.733 | 9.60 ± 47.411 |
| Change at 168 hours | -46.80 ± 23.708 | NA ± NA | 6.82 ± 29.703 | -20.40 ± 24.212 |
| Change at 216 hours | -44.10 ± 35.056 | 13.87 ± 15.597 | -4.90 ± 43.425 | NA ± NA |
| Change at 288 hours | -38.40 ± 33.032 | NA ± NA | 2.58 ± 32.591 | NA ± NA |
| Change at 648 hours | -34.30 ± 45.276 | NA ± NA | 25.17 ± 30.641 | -26.93 ± 45.377 |
Von Willebrand factor (vWF or VWF) is a protein that is one of several components of the coagulation system that work together, to stop bleeding within the body. VWF:RCo assay is a test that measures the activity of the VWF in a plasma sample in terms of how well it is able to clump platelets together in the presence of the antibiotic ristocetin. Change from baseline in vWF:RCo concentration was measured at different timepoints. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the dose of IP. Change from baseline was calculated by subtracting the baseline value from the post-dose value.
| Percentage of vWF RCo | Placebo | TAK-755: 40 IU/kg | TAK-755: 80 IU/kg | TAK-755: 160 IU/kg |
|---|---|---|---|---|
| Change at 0.25 hours | -6.78 ± 8.107 | -7.40 ± 10.802 | -6.06 ± 14.134 | -3.50 ± 13.365 |
| Change at 1 hour | -10.08 ± 11.346 | -7.80 ± 9.242 | 6.63 ± 31.637 | -4.60 ± 8.285 |
| Change at 3 hours | -9.75 ± 5.047 | -20.80 ± 72.904 | -10.10 ± 7.833 | -7.00 ± 10.835 |
| Change at 8 hours | 0.28 ± 34.209 | -34.80 ± 63.461 | -17.36 ± 34.424 | -8.00 ± 14.178 |
| Change at 24 hours | 8.30 ± 5.582 | 20.07 ± 36.049 | 9.32 ± 18.590 | -1.20 ± 26.771 |
| Change at 72 hours | -8.03 ± 8.176 | 20.17 ± 22.167 | 8.60 ± 9.908 | -11.30 ± 11.895 |
| Change at 120 hours | 4.33 ± 15.284 | NA ± NA | -32.33 ± 50.707 | -0.55 ± 11.301 |
| Change at 168 hours | -9.87 ± 6.217 | NA ± NA | 0.97 ± 7.227 | 15.00 ± 9.367 |
| Change at 216 hours | -15.90 ± 20.132 | 13.20 ± 37.091 | 9.35 ± 8.005 | 7.08 ± 22.733 |
| Change at 288 hours | -22.33 ± 11.712 | NA ± NA | 8.58 ± 3.812 | 7.83 ± 36.533 |
| Change at 648 hours | -17.03 ± 10.801 | NA ± NA | 9.43 ± 10.112 | -12.83 ± 83.921 |
Blood samples were collected to analyze platelet count. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the dose of IP. Thechange from baseline was calculated by subtracting the baseline value from the post-dose value.
| 10^9 cells per liter | Placebo | TAK-755: 40 IU/kg | TAK-755: 80 IU/kg | TAK-755: 160 IU/kg |
|---|---|---|---|---|
| Change at 3 hours | -39.40 ± 35.795 | 3.50 ± 27.111 | -42.80 ± 27.151 | -32.00 ± 19.511 |
| Change at 8 hours | -33.96 ± 29.535 | 11.40 ± 24.309 | -38.42 ± 33.679 | -23.77 ± 25.325 |
| Change at 24 hours | -1.60 ± 38.946 | 22.88 ± 36.779 | -11.83 ± 55.654 | -18.50 ± 25.265 |
| Change at 72 hours | -20.80 ± 61.378 | 36.35 ± 19.025 | -7.10 ± 81.770 | -40.75 ± 64.691 |
| Change at 120 hours | 4.50 ± 100.018 | 40.83 ± 35.617 | 18.94 ± 104.933 | -47.25 ± 61.927 |
| Change at 168 hours | -38.40 ± 94.648 | 22.33 ± 58.046 | 20.35 ± 122.803 | -73.33 ± 97.007 |
| Change at 288 hours | -42.00 ± 97.060 | 17.67 ± 10.408 | 6.17 ± 105.447 | -50.75 ± 70.296 |
| Change at 648 hours | -116.40 ± 232.119 | 29.00 ± 27.313 | 6.93 ± 77.027 | 3.75 ± 51.344 |
The plasma free hemoglobin test measures the level of hemoglobin in the plasma (that is, not contained within the red blood cells). Baseline was defined as the last non-missing measurement obtained prior to the date and time of the dose of IP. Change from baseline was calculated by subtracting the baseline value from the post-dose value.
| milligrams per deciliter (mg/dL) | Placebo | TAK-755: 40 IU/kg | TAK-755: 80 IU/kg | TAK-755: 160 IU/kg |
|---|---|---|---|---|
| Change at 3 hours | -5.23 ± 21.732 | -8.98 ± 23.930 | NA ± NA | -106.15 ± 216.380 |
| Change at 8 hours | -11.28 ± 18.671 | -30.58 ± 34.219 | NA ± NA | -147.80 ± 251.263 |
| Change at 24 hours | -3.88 ± 21.390 | -34.28 ± 36.621 | -44.77 ± 47.417 | -105.95 ± 214.072 |
| Change at 72 hours | -9.23 ± 22.105 | -44.93 ± 35.400 | -49.27 ± 47.550 | -108.30 ± 218.455 |
| Change at 120 hours | -14.70 ± 27.120 | NA ± NA | -47.47 ± 48.187 | -98.18 ± 226.371 |
| Change at 168 hours | -10.60 ± 23.047 | -44.37 ± 50.024 | -41.37 ± 47.933 | -123.83 ± 274.097 |
| Change at 288 hours | -8.05 ± 25.683 | -46.47 ± 43.714 | -46.67 ± 47.013 | 5.17 ± 4.319 |
| Change at 648 hours | 13.30 ± 53.656 | -26.43 ± 45.465 | -43.83 ± 50.519 | -130.87 ± 265.316 |
Change from baseline in plasma thrombospondin levels over time was reported. Baseline was defined as the last non-missing measurement obtained prior to the date and time of the dose of IP. Change from baseline was calculated by subtracting the baseline value from the post-dose value.
| nanograms per milliliter (ng/mL) | Placebo | TAK-755: 40 IU/kg | TAK-755: 80 IU/kg | TAK-755: 160 IU/kg |
|---|---|---|---|---|
| Change at 3 hours | 840.4 ± 3979.24 | -628.5 ± 1420.49 | -1177.2 ± 1730.05 | -736.3 ± 860.29 |
| Change at 8 hours | -1892.8 ± 3500.43 | -604.5 ± 1763.64 | -1471.8 ± 1274.07 | -1290.0 ± 1060.98 |
| Change at 24 hours | -934.0 ± 1815.42 | -408.0 ± 1140.98 | -1077.0 ± 1699.60 | -1567.8 ± 957.61 |
| Change at 72 hours | -701.4 ± 2560.18 | -651.8 ± 1208.59 | -1080.0 ± 1945.58 | -1406.0 ± 843.31 |
| Change at 120 hours | -1075.0 ± 1357.88 | -1428.7 ± 1892.45 | -331.8 ± 3735.24 | 1351.8 ± 5880.93 |
| Change at 168 hours | -3886.0 ± 3999.22 | -847.0 ± 1728.41 | -1623.7 ± 1569.60 | -687.5 ± 1373.36 |
| Change at 288 hours | -103.0 ± 1974.37 | -482.0 ± 1150.09 | -1290.7 ± 1723.60 | -903.5 ± 1232.02 |
| Change at 648 hours | -2857.0 ± 4236.96 | -766.0 ± 1948.34 | -909.7 ± 1082.66 | 525.5 ± 3358.11 |
Collected over From date of signing informed consent up to end of study visit (Day 28). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| TAK-755: 40 IU/kg | 0/4 (0%) | 1/4 (25%) | 2/4 (50%) |
| TAK-755: 80 IU/kg | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| TAK-755: 160 IU/kg | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Event | Placebo | TAK-755: 40 IU/kg | TAK-755: 80 IU/kg | TAK-755: 160 IU/kg |
|---|---|---|---|---|
| Sickle cell anaemia with crisisBlood and lymphatic system disorders | 0/5 | 1/4 | 0/6 | 0/4 |
| Event | Placebo | TAK-755: 40 IU/kg | TAK-755: 80 IU/kg | TAK-755: 160 IU/kg |
|---|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 0/5 | 0/4 | 2/6 | 0/4 |
| HeadacheNervous system disorders | 0/5 | 0/4 | 2/6 | 0/4 |
| Abdominal painGastrointestinal disorders | 0/5 | 0/4 | 0/6 | 1/4 |
| Alanine aminotransferase increasedInvestigations | 0/5 | 1/4 | 0/6 | 0/4 |
| Aspartate aminotransferase increasedInvestigations | 0/5 | 1/4 | 0/6 | 0/4 |
| Blood lactate dehydrogenase increasedInvestigations | 0/5 | 1/4 | 0/6 | 0/4 |
| DizzinessNervous system disorders | 0/5 | 1/4 | 0/6 | 0/4 |
| Fibrin D dimer increasedInvestigations | 0/5 | 0/4 | 0/6 | 1/4 |
| Foot fractureInjury, poisoning and procedural complications | 0/5 | 1/4 | 0/6 | 0/4 |
| HypokalaemiaMetabolism and nutrition disorders | 0/5 | 1/4 | 0/6 | 0/4 |
The Safety Analysis Set (SAS) included all participants randomized and who received any dose of the investigational product (IP).
| Age, Categorical(Participants) | Placebo | TAK-755: 40 IU/kg | TAK-755: 80 IU/kg | TAK-755: 160 IU/kg | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 5 | 4 | 6 | 4 | 19 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Placebo | TAK-755: 40 IU/kg | TAK-755: 80 IU/kg | TAK-755: 160 IU/kg | Total |
|---|---|---|---|---|---|
| Female | 3 | 1 | 3 | 1 | 8 |
| Male | 2 | 3 | 3 | 3 | 11 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | TAK-755: 40 IU/kg | TAK-755: 80 IU/kg | TAK-755: 160 IU/kg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 5 | 4 | 6 | 4 | 19 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | TAK-755: 40 IU/kg | TAK-755: 80 IU/kg | TAK-755: 160 IU/kg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 4 | 6 | 4 | 19 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Oct 2019 to primary completion in Oct 2022, 36 months.
Results were first posted in Apr 2024, 1 year 5 months after primary completion.
Of 28 industry-sponsored phase 1 interventional studies under Anemia, Sickle Cell, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's 36 months is above that.
Counting every sponsor, half of 58 studies reached it within 36 months; a quarter within 18 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apadamtase alfa